(Q38941681)

https://doi.org/10.1038/s41388-022-02287-w

7 September 2017

1 reference

29 December 2023

title

FOXC2 promotes colorectal cancer metastasis by directly targeting MET. (English)

1 reference

7 September 2017

1 reference

1 reference

1 reference

Y-M Cui

1

1 reference

7 September 2017

H-L Jiao

2

1 reference

7 September 2017

Y-P Ye

3

1 reference

7 September 2017

C-M Chen

4

1 reference

7 September 2017

J-X Wang

5

1 reference

7 September 2017

N Tang

6

1 reference

7 September 2017

T-T Li

7

1 reference

7 September 2017

J Lin

8

1 reference

7 September 2017

L Qi

9

1 reference

7 September 2017

P Wu

10

1 reference

7 September 2017

S-Y Wang

11

1 reference

7 September 2017

M-R He

12

1 reference

7 September 2017

L Liang

13

1 reference

7 September 2017

X-W Bian

14

1 reference

7 September 2017

W-T Liao

15

1 reference

7 September 2017

Y-Q Ding

16

1 reference

7 September 2017

language of work or name

English

0 references

publication date

10 November 2014

1 reference

7 September 2017

1 reference

7 September 2017

volume

34

1 reference

7 September 2017

issue

33

1 reference

7 September 2017

page(s)

4379-4390

1 reference

7 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Regorafenib for metastatic colorectal cancer - Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Molecular origins of cancer: Molecular basis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The Role of FoxC2 Transcription Factor in Tumor Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The Foxc2 transcription factor regulates tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Metastasis: from dissemination to organ-specific colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Tumor metastasis: molecular insights and evolving paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The Met pathway: master switch and drug target in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

c-Met is essential for wound healing in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin β1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

HOXB7 as a prognostic factor and mediator of colorectal cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Clinical, biological, and molecular aspects of metastasis in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Targeting the c-MET signaling pathway for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.368

Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas

31 March 2020

1 reference

12 December 2020

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer

1 reference

12 December 2020

MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

1 reference

12 December 2020

c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.

1 reference

12 December 2020

Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer

1 reference

12 December 2020

Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.

1 reference

12 December 2020

Orthotopic mouse model of colorectal cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2014.368

1 reference

Dimensions Publication ID

7 September 2017

1038268991

0 references

1 reference